Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6433618

COc1ccccc1CN(CC(=O)OC(C)(C)C)S(=O)(=O)c1ccc2c(Cl)cnc(NC(=N)N)c2c1.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLAU P00749 7/20 0.42
TP53 P04637 1/20 0.38
TAS2R14 Q9NYV8 4/20 0.37
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KMT2A Q03164 1/20 0.36
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
MMP13 P45452 1/20 0.36
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
THRB P10828 1/20 0.35
PLG P00747 2/20 0.35
PLAT P00750 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6437834 0.92 PLAU (0.50) PLAUTP53TAS2R14MAPTSMN1; SMN2
SCHEMBL6437835 0.90 PLAU (0.42) PLAUTP53TAS2R14MAPTSMN1; SMN2
Trifluoroacetic Acid SCHEMBL7451293 0.89 PLAU (0.40) PLAUTP53TAS2R14MAPTSMN1; SMN2
SCHEMBL6436490 0.87 PLAU (0.44) PLAUTAS2R14MAPTSMN1; SMN2ALDH1A1
SCHEMBL6432627 0.86 PLAU (0.56) PLAUMAPTSMN1; SMN2KMT2AMMP1
SCHEMBL6434470 0.84 PLAU (0.44) PLAUALDH1A1PLGPLAT
SCHEMBL6438243 0.84 TP53 (0.45) PLAUTP53TAS2R14MAPTSMN1; SMN2
Trifluoroacetic Acid SCHEMBL6432841 0.83 PLAU (0.52) PLAUTAS2R14MAPTSMN1; SMN2KMT2A
SCHEMBL6438996 0.83 PLAU (0.46) PLAUSMN1; SMN2KMT2AALDH1A1LMNA
SCHEMBL6437213 0.83 PLAU (0.46) PLAUTAS2R14MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885TP53 298/4885TAS2R14 2998/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885TP53 298/4885TAS2R14 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.